A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic C… (NCT07135544) | Clinical Trial Compass
RecruitingPhase 2
A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
China37 participantsStarted 2025-08-14
Plain-language summary
This is an exploratory and prospective study, with the research subjects being patients with initially untreated and unresectable biliary tract tumors. The efficacy and safety of the treatment regimen consisting of Adebrelimab monoclonal antibody combined with targeted therapy and systemic chemotherapy were investigated.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN);
. Aspartate aminotransferase (AST) and alanine aminotransferase ≤ 2.5 x ULN;
. Albumin ≥ 3 g/dL
. Creatinine ≤ 1.5 x ULN 9. Patients can understand and sign the informed consent form to participate in the trial study; good compliance.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial combines three treatments — adebrelimab, apatinib, and chemotherapy — all at once for biliary tract cancer that can't be surgically removed yet; can you help me understand what's already known about the safety of this particular combination, and what side effects I should be most prepared for?
2Since this is a Phase 2 trial, it's still in relatively early stages of testing this regimen — what does that mean for how much we know about whether it actually helps people with my type of biliary tract cancer compared to standard treatments?
3The trial is measuring something called objective response rate, which looks at tumor shrinkage — if the tumor does shrink enough, does that realistically open up the possibility of surgery later, and how would my care team decide if that point has been reached?
4Are there currently approved standard-of-care options for initially unresectable biliary tract cancer that I should consider first, or would joining this trial be a reasonable alternative to discuss alongside those?
5This is a multicenter study — which sites are participating, and is the travel or scheduling burden of receiving this combination regimen something I should factor into my decision about whether this trial fits my situation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
ORR
Timeframe: At the end of Cycle 6 and 10 (each cycle is 21 days)